Date Time
Baylor and TCH researchers honored with AACR Team Science Award
The American Association for Cancer Research (AACR) has recognized the St. Baldrick’s Foundation-Stand Up To Cancer Pediatric Cancer Dream Team with the 2021 AACR Team Science Award. Baylor College of Medicine and Texas Children’s Cancer Center team leader Dr. Nabil Ahmed and researchers Dr. Meenakshi Hegde, Dr. Sujith Joseph, and Dr. Will Parsons are among those recognized. Bambi Grilley and Melanie Frost Moll also were recognized for their contributions to the team as advocates of childhood cancer research.
In early 2013, the St. Baldrick’s Foundation and Stand Up To Cancer (SU2C) collaborated to create a Pediatric Cancer Dream Team to help develop new immunotherapy approaches for high-risk childhood cancers. The collaboration has resulted in 319 peer-reviewed published manuscripts, 44 patent applications, the generation of more than $118 million in additional grant funding, the creation of a new ped
Retired Meriden firefighter shaves her head for 14th year to fight cancerÂ
Retired Meriden firefighter shaves her head for 14th year to fight cancerÂ
Ellie Bender takes an electric shaver to Maggie Bender, her daughter, as Maggie s cousin, barber Scott Lockman, looks on. Jessica Simms, special to the Record-Journal Advertisement
Maggie Bender gets her head shaved by barber Scott Lockman, her cousin, April 11, 2021. Bender shaved her head as part of a fundraiser for the St. Baldrick s Foundation. | Jessica Simms, Special to the Record-Journal
Maggie Bender gets her head shaved by barber Scott Lockman, her cousin, April 11, 2021. Bender shaved her head as part of a fundraiser for the St. Baldrick s Foundation . | Jessica Simms, Special to the Record-Journal
Deadly Brain Tumor: Survival Extended by Oncolytic Virus Product medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
PHILADELPHIA, and BIRMINGHAM, Ala., April 12, 2021 /PRNewswire/ Treovir, an immuno-oncology company that is developing and plans to commercialize G207 for recurrent glioblastoma in children, announced today that G207, an oncolytic HSV immunotherapy, was well tolerated with evidence of clinical effectiveness in a phase 1 study of 12 pediatric patients with recurrent high-grade glioma. Data from the phase 1 study (NCT02457845) are being presented by Gregory Friedman, M.D., professor in the Department of Pediatrics at the University of Alabama at Birmingham, during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15. Data from this trial have been published in the
Treovir Announces Positive Results of Phase 1 Study of G207 in Pediatric Patients with Recurrent High-Grade Glioma prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.